HOME >> BIOLOGY >> NEWS
Tibetans retain resistance to the oxygen-deficient disorder hypoxia regardless of altitude

New Orleans -- For thousands of years, the overwhelming majority of Tibetans have remained at the roof of the world, characterized by average altitudes in excess of 12,000 feet. Living in this hypoxic environment, has necessitated that humans and animals adapt, developing mechanisms to compensate for low oxygen levels and facilitate metabolism and other physiological functions.

For the individual permanently residing at sea level, hypoxia can be caused by external factors, such as a sudden arrival in Tibet, or by "internal impairments," within the body where cells receive insufficient oxygen. Regardless of the cause of the hypoxia, a wide range of disorders may occur.

How can Tibetans function normally at altitudes that would eventually capacity the rest of us? It is known that organisms may adjust who body functions, modify some metabolic pathways, and change the sensitivity of the "injury threshold" to increase a tolerance to hypoxia. But what is unclear is whether that adjustment is acclimatization, capable of occurring during an extended period in a high altitude environment, or adaptation, requiring several generations in high altitudes for tolerance to occur.

Tibet and its native population have previously offered researchers a "natural laboratory" for the study of hypoxia, the environment, and physiological responses to both. Past findings include verification that Tibetans are adaptive in nature, and have significantly less polycythemia (excessive red blood cells) and hypoventilation, normally found in "lowlanders'" mountain sickness. To compare genetic differences and resistant reactions between Tibetans and lowlanders could offer clues for preventing hypoxia, whether it is caused by a change in environment or as a result of the body's processes.

The Study
The authors of the study, "Intrinsic Characteristic Tolerance to Acute Hypoxia in Tibetans after Migrating to Low Altitude," are Zhao-Nian Zhou, J.G. Zhe
'"/>

Contact: Donna Krupa
703-967-2751
American Physiological Society
22-Apr-2002


Page: 1 2 3

Related biology news :

1. How do animals exposed to 24-hour light retain their wake-sleep habits?
2. Study: Stroke victims may retain continuous motion ability
3. Master of antimalarial resistance
4. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
5. Evolvability could be a driving force in drug resistance
6. Insecticide resistance: A constraint on evolutionary change
7. New drug shows promise against Gleevec resistance in mice
8. New milestones on the path to conquering HIV drug resistance (AIDS)
9. Study investigates breast cancer resistance to tamoxifen and possible way to reverse it
10. Antibiotic resistance risk from triclosan questioned
11. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease

Post Your Comments:
(Date:5/21/2013)... the nation,s land and water resources could likely support ... 25 billion gallons of algae-based fuel a year in ... , The findings come from an in-depth look at ... significant amounts of algae in large, specially built shallow ... issue of Environmental Science and Technology , published ...
(Date:5/21/2013)... a class of pharmaceuticals can both prevent and treat ... as "TSPO ligands," are currently used for certain types ... TSPO ligand in young adult mice when pathology was ... pathology was quite severe," said lead researcher Christian Pike ... reduced measures of pathology and improved behavior at both ...
(Date:5/21/2013)... all types become most deadly when they metastasize and ... this stage, it becomes very difficult for doctors to ... Now, researchers at the University of Missouri have found ... tumor cells wherever they may be in the body. ... MU College of Veterinary Medicine, says being able to ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... study led by George Washington University Professor Tianshu ... ice in small droplets is strongly size-dependent, an ... nanoscale. The formation of ice at the nanoscale ... answer also has important implications for climate research ... ice from supercooled water is generally initiated by ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...
(Date:5/21/2013)... Md. , May 21, 2013  MacroGenics, ... 1 study of margetuximab (MGAH22), an Fc-modified chimeric ... tumors expressing the HER2 oncoprotein," will be presented ... Society of Clinical Oncology during the Developmental Therapeutics ... 3 at 4:15 – 4:30 PM.  The presentation ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: